Description

Listing of 8,124,698 equity shares of Ind-Swift Laboratories Limited pursuant to amalgamation scheme with Ind-Swift Limited, effective December 5, 2025.

Summary

BSE has announced the listing of 8,124,698 new equity shares of Rs. 10/- each of Ind-Swift Laboratories Limited (Scrip Code: 532305) effective December 5, 2025. These shares have been issued pursuant to a Scheme of Amalgamation between Ind-Swift Limited (Transferor Company) and Ind-Swift Laboratories Limited (Transferee Company) under Sections 230-232 of the Companies Act, 2013.

Key Points

  • 8,124,698 equity shares of Rs. 10/- each to be listed
  • Scrip Code: 532305
  • ISIN: INE915B01019
  • Distinct Numbers: 73486861 to 81611558
  • Shares issued under amalgamation scheme between Ind-Swift Limited and Ind-Swift Laboratories Limited
  • Corporate action governed by Sections 230-232 of Companies Act, 2013

Regulatory Changes

No regulatory changes. This is a corporate action notification for listing of securities pursuant to an approved amalgamation scheme.

Compliance Requirements

Trading members are informed that the new securities are permitted for trading on the Exchange with effect from December 5, 2025.

Important Dates

  • Date of Allotment: August 25, 2025
  • Trading Commencement Date: December 5, 2025 (Friday)
  • Notice Date: December 4, 2025

Impact Assessment

Market Impact: Medium - The listing represents approximately 8.1 million new shares entering the market following the amalgamation. This increases the total tradable shares of Ind-Swift Laboratories Limited.

Shareholder Impact: Shareholders of the transferor company (Ind-Swift Limited) have received shares in the transferee company (Ind-Swift Laboratories Limited) as part of the amalgamation scheme.

Trading Impact: The new shares will be available for trading from December 5, 2025, which may affect liquidity and trading volumes in the scrip.

Impact Justification

Corporate action involving amalgamation and listing of significant number of shares but limited to single company without broad market impact